We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An adaptive clinical trial conducted by Merck saved the company $70.8 million compared with what a hypothetical traditionally designed study would have cost, according to a company analysis.